Navigation Links
FDA Confirms Seizure of Eyelash Product Was Not Prompted by Reports of Adverse Effects
Date:11/20/2007

HENDERSON, Nev., Nov. 20 /PRNewswire/ -- FDA spokesman, Brad Swezey, affirmed to the Wall Street Journal (WSJ) yesterday that the FDA had not received any reports of patient injuries or adverse effects related to use of the eyelash product the agency seized last Friday.

According to its November 16, 2007, news release, the FDA seized an eyelash product (not made by Athena Cosmetics) because the agency had concerns that an ingredient in the product, bimatoprost, could possibly have deleterious side effects if it were improperly used in the eye with a medication used to treat glaucoma that also contains bimatoprost. As affirmed by Mr. Swezey in a November 19th WSJ article, the FDA did not seize the eyelash product because the FDA or the company that made the product had received reports of any of the serious side effects listed in the FDA's news release.

The FDA's action has created some public concern about the safety of similar eyelash products sold by Athena Cosmetics, Inc. and other companies. Athena Cosmetics wants to assure its customers that, as confirmed by the FDA for the product it seized, there have been no reports of patient injuries or significant adverse effects from thousands of satisfied RevitaLash(R) customers. To the contrary, only a very small number of RevitaLash(R) consumers have reported minor, temporary side effects such as irritation or redness. In addition, the safety of RevitaLash(R) has been tested in two clinical tests conducted by a reputable research laboratory. No adverse reactions were observed in either clinical study of RevitaLash(R).

RevitaLash(R) was developed by an ophthalmologist, Dr. Michael Brinkenhoff, the founder of Athena Cosmetics. As a practicing physician, Dr. Brinkenhoff formulated RevitaLash(R) with safety as the highest priority. Thousands of happy and satisfied customers have safely used RevitaLash(R) to enhance the beauty of their eyelashes. While Athena Cosmetics is confident that RevitaLash(R) is safe, because of possible public concern over bimatoprost created by the FDA's news release, we have decided to stop selling the current formulation of RevitaLash(R). Fortunately, we had been developing new formulations as part of our ongoing commitment to product excellence and customer satisfaction. To minimize disruption to our loyal customers we will accelerate the launch of our reformulated RevitaLash(R) and are now targeting a mid-December launch. We are excited about our new and improved RevitaLash(R) and remain committed to giving our customers the best -- and safest -- product possible.


'/>"/>
SOURCE Athena Cosmetics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
2. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
3. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
4. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
5. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
6. OTC Anti-Aging Products: Hype or Hope?
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
9. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
10. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
11. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016 AAIPharma Services Corp./Cambridge Major Laboratories, ... and development services for the pharmaceutical and biotechnology ... capacity in its Charleston, SC ... several recent investments. Charleston ... line with small-scale lyophilization. The site has invested ...
(Date:2/11/2016)... ANKENY, Iowa , 11 de fevereiro de ... a inauguração de sua fábrica de soroalbumina bovina ... Nova Zelândia. A fábrica fica na Ilha Norte ... Loop "), desenvolvido e estabelecido na fábrica da ... Iowa . O projeto e instalação dos ...
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets ... (APAC) breast cancer market will experience considerable expansion ... at a Compound Annual Growth Rate (CAGR) of 8.5%. ... - states that the Asia-Pacific ... billion in 2014 to $3.4 billion by 2021, at a ...
Breaking Medicine Technology:
(Date:2/12/2016)... , ... February 12, 2016 , ... Donor Network West, ... California and Nevada, announced a partnership with San Ramon Regional Medical Center. Under the ... hospital’s facilities as a way to accommodate a more certain time frame for donor ...
(Date:2/12/2016)... TX (PRWEB) , ... February 12, 2016 , ... ... of southwest Houston and surrounding communities by continuing it’s commitment to act as ... Family Promise. The organization works closely with area homeless families to fulfill immediate ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... Strategies for Health Plans and PBMs,” an upcoming Feb. 24 webinar that will ... access in big-dollar therapeutic categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi ...
(Date:2/12/2016)... ... February 12, 2016 , ... A lot has been ... years. A president has access to health and wellness resources most Americans could ever ... no single individual has a schedule as frenetic as the U.S. President. , ...
(Date:2/12/2016)... ... February 12, 2016 , ... The aging population ... of long term care. With that, says Patrick Loughney, president of Longtree ... roles in long term care environments. His company, which offers prep courses and ...
Breaking Medicine News(10 mins):